# Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

> **NCT01016262** · PHASE3 · TERMINATED · sponsor: **Forest Laboratories** · enrollment: 119 (actual)

## Conditions studied

- Proctitis, Ulcerative

## Interventions

- **DRUG:** MAX-002
- **DRUG:** Placebo
- **DRUG:** Canasa®

## Key facts

- **NCT ID:** NCT01016262
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-30
- **Primary completion:** 2011-07-31
- **Final completion:** 2011-09-30
- **Target enrollment:** 119 (ACTUAL)
- **Why stopped:** The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01016262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01016262, "Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01016262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*